| Toll-like receptor signaling in cell proliferation and survival X Li, S Jiang, RI Tapping Cytokine 49 (1), 1-9, 2010 | 375 | 2010 |
| Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling Y Guan, DRE Ranoa, S Jiang, SK Mutha, X Li, J Baudry, RI Tapping The Journal of Immunology 184 (9), 5094-5103, 2010 | 323 | 2010 |
| TLR10 is a negative regulator of both MyD88-dependent and-independent TLR signaling S Jiang, X Li, NJ Hess, Y Guan, RI Tapping The Journal of Immunology 196 (9), 3834-3841, 2016 | 147 | 2016 |
| TLR10 is a B cell intrinsic suppressor of adaptive immune responses NJ Hess, S Jiang, X Li, Y Guan, RI Tapping The Journal of Immunology 198 (2), 699-707, 2017 | 49 | 2017 |
| BCG in bladder cancer immunotherapy S Jiang, G Redelman-Sidi Cancers 14 (13), 3073, 2022 | 40 | 2022 |
| Early stage cancer in older adults: Prostate—Avoiding overtreatment and undertreatment V Narayan, S Jiang, CA Warlick The Cancer Journal 23 (4), 238-241, 2017 | 15 | 2017 |
| Racial disparities and considerations for active surveillance of prostate cancer S Jiang, V Narayan, C Warlick Translational Andrology and Urology 7 (2), 214, 2018 | 13 | 2018 |
| Risk of genitourinary malignancy in the renal transplant patient S Jiang, S Regmi, S Jackson, C Calvert, S Jarosek, T Pruett, C Warlick Urology 145, 152-158, 2020 | 5 | 2020 |
| Structure of phage protein BC1872 from Bacillus cereus, a singleton with new fold R Zhang, G Joachimiak, S Jiang, A Cipriani, F Collart, A Joachimiak Proteins: Structure, Function, and Bioinformatics 64 (1), 280-283, 2006 | 4 | 2006 |
| Management of duodenal involvement during retroperitoneal lymph node dissection for germ cell tumors JM Jacob, C Cary, S Jiang, RS Foster, MG House Urology 99, 169-173, 2017 | 3 | 2017 |
| Neoadjuvant Systemic Therapy in Localized and Locally Advanced Renal Cell Carcinoma S Khaleel, S Jiang, RR Kotecha, AA Hakimi Frontiers in Urology 2, 864778, 2022 | 2 | 2022 |
| Microbial cancer immunotherapy reprograms hematopoietic stem cells to enhance anti-tumor immunity AW Daman, AC Antonelli, G Redelman-Sidi, L Paddock, JG Cheong, ... BioRxiv, 2024.03. 21.586166, 2024 | 1 | 2024 |
| Adverse pathologic features impact survival outcomes for small renal masses following nephrectomy S Khaleel, H Truong, S Jiang, KL Paul, B Davelman, D Gordon, ... Urologic Oncology: Seminars and Original Investigations 41 (9), 391. e5-391. e11, 2023 | 1 | 2023 |
| Human epidermal growth factor receptor 2 (HER2) and fibroblast growth factor receptor 3 (FGFR3) mutations to reveal biological pathways in urothelial carcinoma. CE Chu, M De Jesus Escano, W Yip, S Jiang, G Iyer, HA Al-Ahmadie, ... Journal of Clinical Oncology 40 (6_suppl), 567-567, 2022 | 1 | 2022 |
| LBA02-04 OUTCOMES AND GENOMIC CHARACTERISTICS OF NEWLY DIAGNOSED HIGH GRADE TA PAPILLARY UROTHELIAL CARCINOMA TREATED WITH INTRAVESICAL CHEMOTHERAPY VS BACILLUS CALMETTE GUERIN … S Jiang, E Manuel de Jesus, P Reisz, EJ Pietzak, C Chu, J Chen, ... Sari, 2023 | | 2023 |
| MP63-08 CLINICAL AND GENOMIC RISK FEATURES OF HIGH GRADE T1 NON-MUSCLE INVASIVE BLADDER CANCER C Chu, J Chen, MDEJ Escano, K Whiting, I Ostrovnaya, S Jiang, W Yip, ... The Journal of Urology 209 (Supplement 4), e874, 2023 | | 2023 |
| LBA02-05 DEFINING INNATE IMMUNE MEMORY IN THE MECHANISM OF BCG IMMUNOTHERAPY FOR BLADDER CANCER S Jiang, G Redelman-Sidi, EJ Pietzak, BH Bochner, M Glickman The Journal of Urology 209 (Supplement 4), e1188, 2023 | | 2023 |
| Response Evaluation Criteria in Tumors of the Bladder (RECIT-Bladder) for future window of opportunity trials as a platform to accelerate drug development. C Gaffney, S Jiang, MR de Jesus, CE Chu, N Benfante, DF Bajorin, ... Journal of Clinical Oncology 41 (6_suppl), 571-571, 2023 | | 2023 |
| DISCORDANCE BETWEEN CLINICAL AND PATHOLOGIC CARCINOMA IN SITU FOR TURBT AND RADICAL CYSTECTOMY IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: IMPLICATIONS FOR BCG … MR Escano, C Chu, S Jiang, W Yip, N Almassi, P Reisz, A Lenis, ... JOURNAL OF UROLOGY 207 (5), E926-E926, 2022 | | 2022 |
| MP59-10 EVALUATING EX VIVO INNATE IMMUNE TRAINING AS A PREDICTIVE MEASURE OF RESPONSIVENESS TO BCG IMMUNOTHERAPY IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER S Jiang, G Redelman-Sidi, EJ Pietzak, BH Bochner, M Glickman The Journal of Urology 207 (Supplement 5), e1005, 2022 | | 2022 |
Richard I TappingAssociate Professor of Microbiology, University of IllinoisVerified email at illinois.edu
